Imkeldi Alternatives Compared
| Imkeldi (imatinib) | Jakafi (ruxolitinib) | Ruxolitinib |
|
|---|
| Imkeldi (imatinib) | Jakafi (ruxolitinib) | Ruxolitinib |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Hypereosinophilic Syndrome... View more |
Prescription only
Prescribed for Polycythemia Vera, Myelofibrosis, Myeloproliferative Disorders, Graft Versus Host Disease. Jakafi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Polycythemia Vera, Myelofibrosis, Myeloproliferative Disorders, Graft Versus Host Disease. Ruxolitinib may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Imkeldi (imatinib) | More about Jakafi (ruxolitinib) | More about Ruxolitinib | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Jakafi has an average rating of 7.5 out of 10 from a total of 33 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 15% reported a negative effect. |
Ruxolitinib has an average rating of 7.3 out of 10 from a total of 43 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 16% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Imkeldi side effects |
View all Jakafi side effects |
View all Ruxolitinib side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Imkeldi prices |
View all Jakafi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
|
N/A |
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other imatinib brands include: Gleevec |
N/A |
Jakafi | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
40 hours |
5.8 hours |
5.8 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 769 drugs are known to interact with Imkeldi:
|
A total of 515 drugs are known to interact with Jakafi:
|
A total of 515 drugs are known to interact with Ruxolitinib:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
November 22, 2024 |
November 16, 2011 |
November 16, 2011 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.